Valuation: Basilea Pharmaceutica AG

Market Cap 657M 809M 701M 599M 1.13B 77.17B 1.15B 7.74B 3.02B 38.63B 3.04B 2.97B 129B P/E 2026 *
14.1x
P/E 2027 * 18.5x
Enterprise Value 507M 624M 541M 462M 870M 59.54B 884M 5.97B 2.33B 29.8B 2.34B 2.29B 99.42B EV / Sales 2026 *
1.93x
EV / Sales 2027 * 1.65x
Free-Float
91.73%
Yield 2026 *
-
Yield 2027 * -
Manager TitleAgeSince
Chief Executive Officer 61 18/04/2018
Director of Finance/CFO 52 09/04/2019
Chief Tech/Sci/R&D Officer 62 30/04/2018
Director TitleAgeSince
Director/Board Member 70 28/11/2011
Chairman 71 08/04/2013
Director/Board Member 73 26/04/2017
Change 5-day change 1-year change 3-year change Capi.($)
0.00%0.00% - - 809M
-0.56%+0.28%+4.02%+16.11% 49.24B
-1.59%+2.12%+460.02%+573.56% 43.3B
-0.85%+7.95%+15.77%+80.09% 40.48B
-0.08%+3.91%+26.96%+9.86% 39.75B
0.00%+3.59%+20.51%+48.00% 32.67B
-3.61%-1.45% - - 16.23B
-2.52%-0.52%+24.35%+118.05% 16.24B
-0.20%+0.32%+3.70%+21.44% 14.04B
-1.09%+5.94%+81.46%+31.15% 13.43B
Average -1.02%+2.30%+79.60%+112.28% 29.49B
Weighted average by Cap. -0.90%+2.71%+96.48%+134.32%

Financials

2026 *2027 *
Net sales 263M 324M 280M 240M 451M 30.88B 458M 3.1B 1.21B 15.46B 1.21B 1.19B 51.57B 267M 329M 285M 244M 459M 31.42B 466M 3.15B 1.23B 15.73B 1.24B 1.21B 52.46B
Net income 51.57M 63.46M 55.01M 47.02M 88.47M 6.06B 89.89M 607M 237M 3.03B 238M 233M 10.11B 39.24M 48.29M 41.86M 35.78M 67.32M 4.61B 68.4M 462M 180M 2.31B 181M 177M 7.7B
Net Debt -150M -185M -160M -137M -257M -17.63B -262M -1.77B -690M -8.82B -693M -678M -29.43B -215M -264M -229M -196M -369M -25.24B -375M -2.53B -988M -12.63B -993M -971M -42.14B
Logo Basilea Pharmaceutica AG
Basilea Pharmaceutica AG Allschwil, formerly known as Basilea Pharmaceutica AG, is a Switzerland-based commercial-stage biopharmaceutical company. The Company operates in one segment, which is the discovery, development, and commercialization of pharmaceutical products to meet the needs of patients with severe bacterial and fungal infections. It launched two hospital brands, Cresemba, which is an intravenous and oral drug for the treatment of invasive fungal infections, and Zevtera, which is an intravenous antibiotic for the treatment of severe bacterial infections, especially pneumonia. Additionally, the Company has several preclinical anti-infective assets in their portfolio. Company's products are present in United States, Canada, Europe, Asia, and Africa.
Employees
-
Trader
Investor
Global
Quality
ESG MSCI
BB